Key result
Tenecteplase was not superior to streptokinase in achieving reperfusion based on non-invasive criteria in patients with STEMI.
Why the study?
Streptokinase is inexpensive but non-fibrin specific and antigenic, whereas bolus agents like tenecteplase are fibrin specific, prompting an evaluation of reperfusion outcomes between the two using non-invasive criteria.
Does tenecteplase improve reperfusion compared to streptokinase in patients with acute ST elevation myocardial infarction?
Observational (n=98)
No
Does tenecteplase improve reperfusion compared to streptokinase in patients with acute ST elevation myocardial infarction?
Tenecteplase did not demonstrate significant superiority over streptokinase for achieving reperfusion in STEMI patients assessed by non-invasive markers.
Answers are grounded in this paper and cite their sources.
No reperfusion superiority observed with tenecteplase versus streptokinase in this STEMI cohort; leaves open need for randomized trials.
Background: Acute ST elevation myocardial infarction occurs due to an occluded coronary artery and can cause death of the patient. The best modality of treating an occluded coronary artery is a primary PCI. Thrombolytic therapy can however render similar results if administered within 2 hours of symptom onset. The concept of pre-hospital thrombolysis is being advocated in the face of current guidelines. Streptokinase (SK) is the most inexpensive of available thrombolytics but is brin non-specic, antigenic and has to be given as an infusion. Reteplase and Tenecteplase(TNK) are brin specic, non- antigenic and can be given as bolus doses making them good agents for prehospital thrombolysis. Aims: We aimed to study reperfusion after thrombolysis with streptokinase vs tenectepalse based on non-invasive criteria.Methods:98 patients were enrolled in this study at a tertiary care centre in a medical college in Southern India between August 2014 to August 2015. This was a nonrandomised quasi-experimental study. 54 patients received streptokinase and 44 received tenecteplase in the study. Results: The reperfusion rate was 46.4% with streptokinase(SK) and 54.3% with Tenecteplase(TNK). Tenecteplase proved to be a better agent for patients aged more than 74 years and for patients who presented later than 2 hours. The difference between SK and TNK was not found to be signicant. Conclusion: Tenecteplase is not superior to Streptokinase in achieving reperfusion in STEMI.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2021) conducted an observational in ST elevation myocardial infarction (n=98). Tenecteplase vs. Streptokinase was evaluated on Reperfusion based on non-invasive criteria. Tenecteplase was not superior to streptokinase in achieving reperfusion based on non-invasive criteria in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: